| Citation: |
YANG Qian, YE Dongxue, MA Yanran, HU Xiaoyuan, LI Hong, ZHOU Xuan, XIANG Fenggang. EIF5A2 Expression in Hepatocellular Carcinoma and Its Relation with Postoperative Survival[J]. Cancer Research on Prevention and Treatment, 2021, 48(6): 617-624. DOI: 10.3971/j.issn.1000-8578.2021.20.1437
|
To detect the expression of EIF5A2 in hepatocellular carcinoma(HCC) and to explore its relation with clinicopathological characters and prognosis of HCC patients.
The expression of EIF5A2 mRNA and protein in 12 pairs of fresh HCC and corresponding non-tumor tissues adjacent to the cancer was examined by qRT-PCR and Western blot. The expression level of EIF5A2 in 284 pairs of HCC and adjacent non-tumor tissues was detected by IHC staining. Then we analyzed between EIF5A2 expression and clinical pathological parameters and prognosis of HCC patients.
The relative expression levels of EIF5A2 mRNA and protein in fresh HCC tissues were significantly higher than those in the corresponding adjacent non-tumor tissues (t=5.305, P=0.0003; t=10.120, P < 0.001); EIF5A2 expression in 284 HCC tissues was significantly higher than that in the corresponding adjacent non-tumor tissues (z=-12.186, P < 0.001). The expression of EIF5A2 was significantly correlated with tumor size (χ2=13.079, P < 0.001), tumor multiplicity (χ2=4.589, P=0.032) and differentiation degree (χ2=4.844, P=0.028). The 3- and 5-year overall survival time and disease-free survival time of the patients with high expression of EIF5A2 were significantly shorter than those with low expression of EIF5A2 (P < 0.001). EIF5A2 was an independent prognostic factor affecting the 3- and 5-year overall survival time and disease-free survival time of HCC patients (P < 0.05).
The up-regulation of EIF5A2 expression may be related with the occurrence and development of hepatocellular carcinoma. The high expression of EIF5A2 is an independent influence factor for poor prognosis and EIF5A2 can be used as a potential molecular marker for predicting the prognosis of HCC patients.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
|
| [2] |
Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2016, 2: 16018.
|
| [3] |
Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer[J]. Cancer, 2016, 122(9): 1312-1337. doi: 10.1002/cncr.29936
|
| [4] |
Zucman-Rossi J, Villanueva A, Nault JC, et al. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma[J]. Gastroenterology, 2015, 149(5): 1226-1239. http://www.ncbi.nlm.nih.gov/pubmed/26099527
|
| [5] |
Wang FW, Guan XY, Xie D. Roles of eukaryotic initiation factor 5A2 in human cancer[J]. Int J Biol Sci, 2013, 9(10): 1013-1020. doi: 10.7150/ijbs.7191
|
| [6] |
Xu G, Yu H, Shi X, et al. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2[J]. BMC Pulm Med, 2014, 14: 174. doi: 10.1186/1471-2466-14-174
|
| [7] |
Liu Y, Du F, Chen W, et al. EIF5A2 is a novel chemoresistance gene in breast cancer[J]. Breast Cancer, 2015, 22(6): 602-607. doi: 10.1007/s12282-014-0526-2
|
| [8] |
Huang PY, Zeng TT, Ban XJ, et al. Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy[J]. BMC Cancer, 2016, 16(1): 669. doi: 10.1186/s12885-016-2714-2
|
| [9] |
Fang Y, Cen JJ, Cao JZ, et al. Overexpression of EIF5A2 in upper urinary tract urothelial carcinoma is a new independent prognostic marker of survival[J]. Future Oncol, 2019, 15(17): 2009-2018. doi: 10.2217/fon-2018-0748
|
| [10] |
He LR, Zhao HY, Li BK, et al. Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage Ⅰ non-small cell lung cancer patients[J]. Int J Cancer, 2011, 129(1): 143-150. http://europepmc.org/abstract/MED/20830705
|
| [11] |
Yang GF, Xie D, Liu JH, et al. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma[J]. Gynecol Oncol, 2009, 112(2): 314-318. http://www.sciencedirect.com/science/article/pii/S009082580800886X
|
| [12] |
Guan XY, Sham JS, Tang TC, et al. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer[J]. Cancer Res, 2001, 61(9): 3806-3809. http://www.ncbi.nlm.nih.gov/pubmed/11325856
|
| [13] |
Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation[J]. Nat Rev Mol Cell Biol, 2010, 11(2): 113-127. http://europepmc.org/abstract/MED/20094052
|
| [14] |
Caraglia M, Park MH, Wolff EC, et al. eIF5A isoforms and cancer: two brothers for two functions?[J]. Amino Acids, 2013, 44(1): 103-109.
|
| [15] |
Li Y, Fu L, Li JB, et al. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma[J]. Gastroenterology, 2014, 146(7): 1701-1713. e9.
|
| [16] |
Meng QB, Peng JJ, Qu ZW, et al. Eukaryotic initiation factor 5A2 and human digestive system neoplasms[J]. World J Gastrointest Oncol, 2019, 11(6): 449-458. http://www.cnki.com.cn/Article/CJFDTotal-WJGP201906001.htm
|
| [17] |
Zheng X, Gao L, Wang BT, et al. Overexpression of EIF5A2 is associated with poor survival and aggressive tumor biology in gallbladder cancer[J]. Histol Histopathol, 2019, 35(6): 579-587. http://www.researchgate.net/publication/342409409_Overexpression_of_EIF5A2_is_associated_with_poor_survival_and_aggressive_tumor_biology_in_gallbladder_cancer
|
| [18] |
Lu J, Zhao HW, Chen Y, et al. Eukaryotic translation initiation factor 5A2 is highly expressed in prostate cancer and predicts poor prognosis[J]. Exp Ther Med, 2019, 17(5): 3741-3747. http://www.ncbi.nlm.nih.gov/pubmed/30988760
|
| [19] |
Yang Q, Ye Z, Zhang Q, et al. Expression of eukaryotic translation initiation factor 5A-2 (eIF5A-2) associated with poor survival in gastric cancer[J]. Tumour Biol, 2016, 37(1): 1189-1195. doi: 10.1007/s13277-015-3894-0
|
| [20] |
Meng QB, Kang WM, Yu JC, et al. Overexpression of eukaryotic translation initiation factor 5A2 (EIF5A2) correlates with cell aggressiveness and poor survival in gastric cancer[J]. PLoS One, 2015, 10(3): 0119229. http://pubmedcentralcanada.ca/pmcc/articles/PMC4368542/
|
Figures(4) / Tables(7)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: